These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37496357)

  • 1. A Story of Serendipities: From Phlorizin to Gliflozins.
    Helvacı Ö; Helvacı B
    Exp Clin Transplant; 2023 Jun; 21(Suppl 2):105-108. PubMed ID: 37496357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].
    Valdes-Socin H; Scheen AJ; Jouret F; Grosch S; Delanaye P
    Rev Med Liege; 2022 Mar; 77(3):175-180. PubMed ID: 35258866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis.
    Leslie BR; Gerwin LE; Taylor SI
    Ann Intern Med; 2019 Sep; 171(6):421-426. PubMed ID: 31525753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering.
    Jörgens V
    Acta Diabetol; 2019 Jan; 56(1):29-31. PubMed ID: 30099672
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
    Pérez López G; González Albarrán O; Cano Megías M
    Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
    Choi CI
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural selectivity of human SGLT inhibitors.
    Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
    Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin Sensitivity-Enhancing Activity of Phlorizin Is Associated with Lipopolysaccharide Decrease and Gut Microbiota Changes in Obese and Type 2 Diabetes (db/db) Mice.
    Mei X; Zhang X; Wang Z; Gao Z; Liu G; Hu H; Zou L; Li X
    J Agric Food Chem; 2016 Oct; 64(40):7502-7511. PubMed ID: 27635781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
    Blaschek W
    Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
    Mudaliar S; Polidori D; Zambrowicz B; Henry RR
    Diabetes Care; 2015 Dec; 38(12):2344-53. PubMed ID: 26604280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
    Maccari R; Ottanà R
    J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Management of Diabetes Mellitus: A Century of Expert Opinions in Cecil Textbook of Medicine.
    Manu P; Rogozea LM; Cernea S
    Am J Ther; 2021 Jun; 28(4):e397-e410. PubMed ID: 34228650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats.
    Freitas HS; D'Agord Schaan B; da Silva RS; Okamoto MM; Oliveira-Souza M; Machado UF
    Nephron Physiol; 2007; 105(3):p42-51. PubMed ID: 17204838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.